FDA Watch: Agency Okays EIA Technology-Based Lyme Assays

 Email not displaying correctly? View it in your browser.
  Lab and Pathology Insider Logo  
September 24, 2019  
placeholder CMS
FDA Watch: Agency Okays EIA Technology-Based Lyme Assays
From National Intelligence Report
Laboratory diagnosis of Lyme disease is based on detecting the presence of antibodies against…
Read More
placeholder EMERGING TESTS
Inside the Industry: Government Report Casts Doubt on Cost-Effectiveness of Leading Genetic Colorectal Cancer Screening Test
From Laboratory Industry Report
Few of the newfangled consumer genetic testing products have had greater commercial success and…
Read More
placeholder REIMBURSEMENT
Medicare Reimbursement: MIPS Bonuses Are Easy to Earn, IF You Can Get into the Program
From Lab Compliance Advisor
On July 11, CMS announced the results of 2018, Year 2 under the Merit-based Incentive Payment System…
Read More
placeholder GENETIC TESTING
Genetic Testing: Multigene Panel Testing Detects Hereditary Risk Variants in Metastatic Breast Cancer Patients
From Diagnostic Testing & Emerging Technologies
The clinical value of performing multigene panel for inherited cancer in patients with metastatic breast cancer has…
Read More
placeholder COMPLIANCE
Genetic Testing Fraud Prosecutions are on the Rise around the Country. Are Your Genetic Testing Practices Compliant?
From G2 Blog
Over the last year, a number of genetic testing fraud investigations and prosecutions have been initiated by…
Read More

For questions concerning delivery of this email, please contact customer service at:
(888) 729-2315 | customerservice@plainlanguagemedia.com

Copyright © 2019, All rights reserved.
Plain Language Media LLLP
PO Box 509, New London, CT 06320